In addition, an upstream block of Ang II via type 1 Ang II receptor blockers, is able to reduce significantly p63RhoGEF and MYPT-1 phosphorylation further confirming that any attempt to reduce ROCK activity is crucial for the progression of cardiovascular-renal remodeling and that patients at high cardiovascular risk such as hypertensive, CKD patients might benefit from the pleiotropic effects of angiotensin receptor blockers [63]. This evidence concerns the gene PPP1R12A and chronic kidney disease.